Arrient Healthcare Pvt Ltd
Glimepiride (2mg) + Metformin (500mg) + Voglibose (0.3mg)
Glimpure MV 2.3 Tablet is a combination of anti-diabetic drugs used to treat type 2 diabetes mellitus in adults, helping to control blood sugar levels.
Tablet
Glimpure MV 2.3 Tablet is a combination of three antidiabetic medicines used to treat type 2 diabetes mellitus in adults. It helps control blood sugar levels in people with diabetes.
Take this medicine in the dose and duration as advised by your doctor. Swallow it as a whole. Do not chew, crush or break it. Glimpure MV 2.3 Tablet is to be taken empty stomach.
No common side effects listed.
It is unsafe to consume alcohol with Glimpure MV 2.3 Tablet.
Glimpure MV 2.3 Tablet is probably unsafe to use during breastfeeding. Limited human data suggests that the drug may pass into the breastmilk and harm the baby.
Glimpure MV 2.3 Tablet may be unsafe to use during pregnancy. Although there are limited studies in humans, animal studies have shown harmful effects on the developing baby. Your doctor will weigh the benefits and any potential risks before prescribing it to you. Please consult your doctor.
Glimpure MV 2.3 Tablet is a combination of three antidiabetic medicines:
Take it with food to lower your chance of having an upset stomach. It can cause hypoglycemia (low blood sugar level) when used with other antidiabetic medicines, alcohol or if you delay or miss a meal. Carry a sugar source with you for immediate relief. Your doctor may check your liver function regularly. Inform your doctor if you develop symptoms such as abdominal pain, loss of appetite, or yellowing of the eyes or skin (jaundice).
Glimpure MV 2.3 Tablet is a combination of three medicines: Glimepiride, Metformin, and Voglibose. This medicine is used in the treatment of type 2 diabetes mellitus (DM). It improves blood glucose levels in adults when taken along with proper diet and regular exercise. Glimepiride lowers blood glucose by increasing insulin release from the pancreas. Metformin works by lowering glucose production in the liver and improving insulin sensitivity. Voglibose is an alpha-glucosidase inhibitor that lowers postprandial (after meals) glucose levels. This combination is not indicated for the treatment of Type 1 DM.
The use of Glimpure MV 2.3 Tablet may cause common side effects such as hypoglycemia (low blood sugar level), nausea, diarrhea, altered taste, flatulence, stomach pain, headache, skin rash, and respiratory tract infection.
Glimpure MV 2.3 Tablet should not be used by patients with known allergies to any of the medicine or excipients. It is also avoided in patients with moderate to severe kidney disease and those with inflammatory bowel disease, colonic ulcerations, and underlying metabolic acidosis including diabetic ketoacidosis.
No, it is not safe to combine alcohol with Glimpure MV 2.3 tablet because it may lower blood sugar levels (hypoglycemia) and increase the risk of lactic acidosis.
Yes, the use of Glimpure MV 2.3 Tablet may lead to hypoglycemia (low blood sugar level). Symptoms include nausea, headache, irritability, hunger, sweating, dizziness, fast heart rate, and feeling anxious or shaky. This is more likely when skipping meals, drinking alcohol, overexerting, or taking other antidiabetic medications alongside it. Regular monitoring of blood glucose levels is crucial. Always keep glucose tablets, honey, or fruit juice readily available.
Store this medicine in its original packaging with a tight seal. Follow the storage instructions provided on the medication label. Do not consume any unused medication, and ensure it is out of reach of pets, children, and unauthorized individuals.